Redeye initiates coverage of ADDvise Group with a base case of SEK 2 per share. We argue that ADDvise is on the path of improving margins and bottom line and significantly strengthening its fundamentals to allow self-financed growth within a few years. It is currently trading at a significant discount from fair value. Covid-19 has had a mixed impact on the company.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/